These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 2605125)

  • 1. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates.
    McFarland JG; Anderson AJ; Slichter SJ
    Br J Haematol; 1989 Nov; 73(3):380-6. PubMed ID: 2605125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical aspects of platelet transfusions.
    Murphy MF; Waters AH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion strategy: use of HLA-matched platelet transfusions for alloimmunized patients.
    Menitove JE; Duquesnoy RJ
    Am J Med Technol; 1981 Feb; 47(2):114-20. PubMed ID: 7223758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions.
    Sintnicolaas K; Löwenberg B
    Br J Haematol; 1996 Mar; 92(4):1005-10. PubMed ID: 8616059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates.
    O'Connell BA; Lee EJ; Rothko K; Hussein MA; Schiffer CA
    Blood; 1992 Jan; 79(2):527-31. PubMed ID: 1730095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet crossmatch testing for donor selection.
    Slichter SJ
    Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet transfusion reaction associated with interdonor HLA incompatibility.
    Eastlund DT; McGrath PC; Burkart P
    Vox Sang; 1988; 55(3):157-60. PubMed ID: 3266389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets.
    Schiffer CA; O'Connell B; Lee EJ
    Blood; 1989 Aug; 74(3):1172-6. PubMed ID: 2752158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
    Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
    Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates.
    Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG
    Transfusion; 1977; 17(6):657-61. PubMed ID: 595123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients.
    Heal JM; Blumberg N; Masel D
    Blood; 1987 Jul; 70(1):23-30. PubMed ID: 3474041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases.
    Klingemann HG; Self S; Banaji M; Deeg HJ; Doney K; Slichter SJ; Thomas ED; Storb R
    Br J Haematol; 1987 May; 66(1):115-21. PubMed ID: 3593647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
    Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloimmunization to public HLA antigens in multi-transfused platelet recipients.
    MacPherson BR; Hammond PB; Maniscalco CA
    Ann Clin Lab Sci; 1986; 16(1):38-44. PubMed ID: 3947028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.
    Boothby AB; Tanner MK; Alswied A; Youngs D; Bribiesca Rodriguez J; Bikkani T; Cha N; Gernsheimer T; Gimferrer I; Hess JR; Sokol-Hessner L; Marivada S; Nash MG; Flegel WA; Vassallo RR; Stroncek DF; Tsang HC; Panch SR
    Blood Adv; 2024 Sep; 8(17):4689-4699. PubMed ID: 39028936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB; Romine M
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.
    Andreu G; Dewailly J; Leberre C; Quarre MC; Bidet ML; Tardivel R; Devers L; Lam Y; Soreau E; Boccaccio C
    Blood; 1988 Sep; 72(3):964-9. PubMed ID: 3416079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.